Clinical trial
Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic…
NCT00004857 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00004857 |
|---|---|
| Title | Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia |
| Official title | A Phase II Study of Fludarabine Induction Followed by CAMPATH-1H Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | alemtuzumab, fludarabine phosphate |
| Enrollment | 86 |
| Start date | Jan 1, 2000 |
| Primary completion | Mar 1, 2003 |
| Completion | Feb 1, 2010 |
| First posted | Dec 11, 2003 |
| Last update posted | Jul 6, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: